SecBot SecBot
8-K ·Filed Nov 9, 2026

PROK

PROKIDNEY CORP.
NEUTRAL
Impact 3/10
Horizonmonths Processed7d 19h ago SEC0001193125-26-452616
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The cash balance decline and S-3 shelf registration signal that ProKidney will likely need to raise capital before mid-2027 to fund operations beyond the Phase 3 readout. Monitor for ATM draws or a follow-on offering, which would be dilutive at the current $1.52 share price.

DirectionNeutral
Confidencehigh
Horizonmonths

REACT

● Neutral Named in this 8-K
Impact
Phase
Phase 3
Time to market
If Phase 3 PROACT 1 data is positive in Q2 2027 and an accelerated approval filing follows, a potential FDA decision could come in late 2027 or 2028. Commercial launch would follow approval.
Next catalyst
None dated

What to watchThe next major catalyst is the Phase 3 PROACT 1 topline data readout, expected in Q2 2027. Positive results could unlock an accelerated approval filing under FDA's RMAT pathway, while a miss would likely devastate the stock given the company is a single-asset developer. A softer near-term event is the KOL virtual event on October 27, 2026, which may provide updated mechanism-of-action data from ASN Kidney Week.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$1.15
T+0 close · Nov 9, 2026 · via day close
Latest settled
−9.57%
T+5 · $1.04
Vs SPY
−7.87%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $1.15entry
  2. T+1 · 7d ago −3.48%α −3.11% · $1.11
  3. T+5 · 20h ago −9.57%α −7.87% · $1.04
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ProKidney reported Q3 2026 cash and marketable securities of $141.9 million, down from $181.6 million at Q2 2026, and updated its investor presentation with Phase 3 PROACT 1 milestones: full enrollment expected Q1 2027, topline eGFR slope data in Q2 2027, and BLA submission in Q1 2028. The company has no revenue and continues to burn cash to fund its clinical trials, with cash runway into mid-2027. The filing is routine for a pre-revenue biotech and does not contain a material change in financial condition or clinical outlook.

Key Facts

  • Cash, cash equivalents and marketable securities as of September 30, 2026 was $141.9 million, compared to $181.6 million at June 30, 2026.
  • Phase 3 PROACT 1 study full enrollment expected Q1 2027 (over 500 patients, up from 470).
  • Topline eGFR slope data for accelerated approval anticipated Q2 2027.
  • BLA submission for accelerated approval expected Q1 2028.
  • Cash runway expected to fund operations into mid-2027.
  • Shares outstanding as of November 6, 2026: 302,381,712 (Class A and B).
  • No revenue or earnings data reported for Q3 2026; the 8-K only discloses the cash balance.
  • S-3 shelf registration filed October 29, 2026, registering up to $650 million in securities including a $200 million ATM facility.

Financial Impact

Cash burn of approximately $39.7 million in Q3 2026 (from $181.6M to $141.9M). No revenue reported.

cashcash runway

Risk Factors

  • Cash runway only into mid-2027; additional financing likely needed before Phase 3 data readout.
  • S-3 shelf registration filed 11 days prior signals potential near-term dilution.
  • No approved products or revenue; clinical trial failure would be binary.
  • Phase 3 PROACT 1 topline data in Q2 2027 is the next major catalyst; any delay or negative result would be material.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
69% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-452616
Document: prok-ex99_1.htm0001193125-26-452616
Document: 0001193125-26-452616-index-headers.html0001193125-26-452616
Document: 0001193125-26-452616-index.html0001193125-26-452616
Document: 0001193125-26-452616.txt0001193125-26-452616
8-K Data (Synthetic)0001193125-26-452616

Track record

13 reports on PROK

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +13.51% at T+1 after the Oct 29, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Bearish 7/10 Entry $1.05 to $1.04 Now $1.04 +0.48% ▲ +0.48% −1.43% vs SPY
  2. Nov 12, 20264d ago 424B5 Bearish 6/10 Entry $1.15 to $1.05 Now $1.04 +9.57% ▲ +9.13% +8.77% vs SPY
  3. Nov 12, 20265d ago EFFECT Bearish 5/10 Entry $1.15 to $1.05 Now $1.04 +9.57% ▲ +9.13% +8.77% vs SPY
  4. Nov 9, 20267d ago 8-K Neutral 3/10 Viewing Entry $1.15 to $1.11 Now $1.04 −9.57% ▼ −3.48% −3.11% vs SPY
  5. Oct 29, 202618d ago 8-K Bearish 6/10 Entry $1.30 to $1.12 Now $1.04 +19.69% ▲ +13.51% +13.03% vs SPY
  6. Oct 29, 202618d ago S-3 Bearish 6/10 Entry $1.30 to $1.12 Now $1.04 +19.69% ▲ +13.51% +13.03% vs SPY
  7. Oct 22, 202625d ago Press Release Neutral 3/10 Entry $1.43 to $1.41 Now $1.04 −27.27% ▼ −1.40% −0.88% vs SPY
  8. Aug 10, 202614w ago 8-K Neutral 5/10 No price data
  9. Aug 10, 202614w ago Press Release Neutral 5/10 Entry $1.61 to $1.48 Now $1.04 −35.40% ▼ −8.07% −8.32% vs SPY
  10. May 15, 202626w ago 8-K Neutral 4/10 No price data
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026